Ab&B fortifies for battle over China’s vaccine market
With proceeds from a Hong Kong IPO, the loss-making biotech is bidding for a piece of China’s fiercely competitive market for flu and human rabies vaccines Key Takeaways: The company’s…
Recent Articles
RELATED ARTICLES
-
Dispute over Covid vaccines casts doubt on Clover Bio recovery
2197.HK -
Everest Medicines drives growth with AI-powered mRNA pipeline
1952.HK
- Anti-toxin provider Jiangxi Institute joins biopharma IPO rush
-
Biogene gets bruised in ‘Battle of the skincare belles’
2367.HK 688363.SHG
-
JD.com sets up Hong Kong bridgehead as real-time retail battle moves overseas
9618.HK JD.US
- Switchbot taps market frenzy for robotic stocks
-
Unisound launches modest IPO into crowded Hong Kong market
9678.HK
